Germany · Delayed Price · Currency is EUR Redcare Pharmacy NV Earnings Call Transcripts
Fiscal Year 2026
-
Q1 2026 saw 18% revenue growth to €849M, with strong Rx and non-Rx performance, improved EBITDA margin, and a rebound in German non-Rx. Guidance remains unchanged amid regulatory uncertainty and early-year volatility, with continued investment in IT and marketing optimization.
Fiscal Year 2025
-
Full-year revenues rose 24% to EUR 2.9 billion, driven by strong Rx growth and logistics expansion. 2026 guidance targets 13%-15% sales growth, Rx Germany revenues above EUR 670 million, and an adjusted EBITDA margin of at least 2.5%.
-
Sales grew 27% year-over-year with strong gains in both Rx and non-Rx segments, and adjusted EBITDA margin reached 2.1% year-to-date. Cash flow and liquidity remain robust, supporting ongoing investments in logistics and automation, while full-year guidance is reiterated.
-
Sales grew 27% year-over-year with record adjusted EBITDA and strong Rx momentum, especially in Germany. Guidance for over 25% sales growth and 2–2.5% EBITDA margin is confirmed, supported by regulatory wins and robust cash flow.
-
Q1 2025 saw 28% sales growth to €717M, driven by RX and ERX, with positive EBITDA and strong customer gains. Guidance for 2025 is reiterated, with margin improvement expected as seasonality and efficiency gains take effect.
Fiscal Year 2024
-
Exceptional 2024 growth was driven by e-Rx adoption in Germany, market leadership in multiple countries, and strong customer metrics. Sales rose 32% to nearly EUR 2.4 billion, with Rx up 64% and adjusted EBITDA at EUR 33 million. 2025 guidance targets >25% sales growth and margin improvement.
-
Sales grew 34% year-over-year to €1.7 billion, with strong eRx momentum in Germany and non-Rx growth at 20%. Adjusted EBITDA margin was 2.3% YTD, and market share in German eRx rose to 0.66% in October. Full-year sales guidance is €2.35–2.5 billion.
-
Q3 saw 21% organic sales growth and a surge in German Rx sales, driven by strong eRx adoption and high repeat order rates. Full-year sales guidance was raised, while EBITDA margin guidance was narrowed due to increased Rx marketing investments. Management remains confident in long-term growth and profitability.